Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

Open access
Kavanagh, Brian, O'Brien, Shaun, Lee, David, Hou, Yafei, Weinberg, Vivian, Rini, Brian, Allison, James P., Small, Eric J., Fong, Lawrence · 2008 · Blood

Abstract

Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) delivers inhibitory signals to activated T cells. CTLA4 is constitutively expressed on regulatory CD4(+) T cells (Tregs), but its role in these cells remains unclear. CTLA4 blockade has been shown to induce antitumor immunity. In this study, we examined the effects of anti-CTLA4 antibody on the endogenous CD4(+) T cells in cancer patients. We show that CTLA4 blockade induces an increase not only in the number of activated effector CD4(+) T cells, but also in the number of CD4(+) FoxP3(+) Tregs. Although the effects were dose-dependent, CD4(+) FoxP3(+) regulatory T cells could be expanded at lower antibody doses. In contrast, expansion of effector T cells was seen only at the highest dose level studied. Moreover, these expanded CD4(+) FoxP3(+) regulatory T cells are induced to proliferate with treatment and possess suppressor function. Our results demonstrate that treatment with anti-CTLA4 antibody does not deplete human CD4(+) FoxP3(+) Tregs in vivo, but rather may mediate its effects through the activation of effector T cells. Our results also suggest that CTLA4 may inhibit Treg proliferation similar to its role on effector T cells. This study is registered at http://www.clinicaltrials.gov/ct2/show/NCT00064129, registry number NCT00064129.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2007-11-125435

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 57 references

Cited by

See all 256

Metadata

Authors
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L.
Affiliations
  • Division of Hematology/Oncology,
  • University of California, San Francisco (US)
  • Memorial Sloan Kettering Cancer Center (US)
Venue
Blood
Published
2008-08-15
Volume
112
Issue
4
Pages
1175-1183
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2033805603
Cited by
256
References
57
Citations by year
2026: 5 · 2025: 8 · 2024: 14 · 2023: 8 · 2022: 12 · 2021: 17 · 2020: 17 · 2019: 15 · 2018: 14 · 2017: 22 · 2016: 12 · 2015: 10 · 2014: 22 · 2013: 16 · 2012: 12
FWCI
7.23
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • University of California, San Francisco
  • National Cancer Institute (P50 CA89520, CA102303, P50CA089520, R01CA102303)
  • National Center for Research Resources (UL1RR024131, RR 024131)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CTLA-4 blockade, anti-CTLA-4 antibody, Foxp3+ regulatory T cells, CD4+ effector T cells, Treg proliferation, Treg suppressive function, dose-dependent effects, cancer immunotherapy, T cell activation, immune checkpoint blockade
MeSH terms
Aged, Aged, 80 and over, Antibodies, Antineoplastic Combined Chemotherapy Protocols, Humans, Lymphocyte Activation, Male, Middle Aged, Neoplasm Metastasis, Prostatic Neoplasms, CD4-Positive T-Lymphocytes, Antigens, CD, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocyte Count, Ki-67 Antigen, Cell Proliferation, T-Lymphocytes, Regulatory, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. https://app.cochat.ai/papers/10.1182/blood-2007-11-125435
The paper
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008). CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. https://doi.org/10.1182/blood-2007-11-125435

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.